AST
ASTRON CONNECT INC
stock CVE

I gave 7 different AI models essentially the same challenge: Pick ONE publicly traded stock that has the highest probability of reaching 10x its current market value over the next 10 years.
The goal wasn’t to find the stock with the craziest upside. It was to find the best combination of starting valuation, growth, TAM, moat, financial strength and realistic execution.
Here are the results:
Claude Sonnet 5 → Oklo (OKLO)
AI data centers are creating enormous demand for reliable electricity, and advanced nuclear could become part of the solution. Oklo is still small enough that successful commercial deployment could dramatically change its valuation.
Runner-up: NuScale (SMR)
Claude Opus 5 → Rocket Lab (RKLB)
Rocket Lab already has real businesses in launch, satellite components and defense. If Neutron succeeds, it could evolve from a launch company into a much larger vertically integrated space infrastructure platform.
Runner-up: Nu Holdings (NU)… I don’t understand this one.
Fable 5.1 → Rocket Lab (RKLB)
Founder-led, strong growth and exposed to long-term commercial space and defense spending. Neutron is the major catalyst that could significantly expand RKLB’s addressable market.
Runners-up: Nebius (NBIS), Oscar Health (OSCR)
Grok 4.6 → Oklo (OKLO)
The thesis is basically that electricity becomes one of the biggest bottlenecks to continued AI expansion. If advanced nuclear becomes an important source of data-center power, Oklo has a massive runway from its relatively small starting size.
Runner-up: Rocket Lab (RKLB)
Gemini → AST SpaceMobile (ASTS)
ASTS is building satellite broadband that connects directly to ordinary smartphones. If successful, it could address billions of mobile subscribers and areas where traditional cellular infrastructure doesn’t economically work.
Runner-up: Rocket Lab (RKLB)
GPT-5.5 → TransMedics (TMDX)
A very different pick. TMDX already has meaningful revenue, profitability and a strong moat combining organ-preservation technology, clinical infrastructure and logistics. The thesis is that it could become the infrastructure platform for organ transplantation.
Runner-up: Hims & Hers (HIMS)
GPT-5.6 → monday.com (MNDY)
The least “moonshot” answer. MNDY already produces strong cash flow, is growing around 20%, has a relatively small valuation and could expand from project management into CRM, service and AI-powered enterprise workflows. The interesting part is that the 10x math only requires roughly mid-teens long-term growth plus margin expansion… I don’t get this one either.
Runner-up: Klaviyo (KVYO)
The closest thing to consensus: Rocket Lab appeared in 4 of the 7 models’ top picks or runner-ups, while Oklo was selected #1 by two models.
What I found more interesting than the individual stocks is how different the approaches were. Some models preferred highly asymmetric bets like nuclear and space, while others favored companies that already have revenue, profitability and a clearer path to compounding.
Apparently the AI-approved path to a 10-bagger portfolio is some combination of rockets, nuclear reactors, organ transplants and project-management software. Seems diversified enough. 😂
Which one would you pick if you had to hold it until 2036?

I gave 7 different AI models essentially the same challenge: Pick ONE publicly traded stock that has the highest probability of reaching 10x its current market value over the next 10 years.
The goal wasn’t to find the stock with the craziest upside. It was to find the best combination of starting valuation, growth, TAM, moat, financial strength and realistic execution.
Here are the results:
Claude Sonnet 5 → Oklo (OKLO)
AI data centers are creating enormous demand for reliable electricity, and advanced nuclear could become part of the solution. Oklo is still small enough that successful commercial deployment could dramatically change its valuation.
Runner-up: NuScale (SMR)
Claude Opus 5 → Rocket Lab (RKLB)
Rocket Lab already has real businesses in launch, satellite components and defense. If Neutron succeeds, it could evolve from a launch company into a much larger vertically integrated space infrastructure platform.
Runner-up: Nu Holdings (NU)… I don’t understand this one.
Fable 5.1 → Rocket Lab (RKLB)
Founder-led, strong growth and exposed to long-term commercial space and defense spending. Neutron is the major catalyst that could significantly expand RKLB’s addressable market.
Runners-up: Nebius (NBIS), Oscar Health (OSCR)
Grok 4.6 → Oklo (OKLO)
The thesis is basically that electricity becomes one of the biggest bottlenecks to continued AI expansion. If advanced nuclear becomes an important source of data-center power, Oklo has a massive runway from its relatively small starting size.
Runner-up: Rocket Lab (RKLB)
Gemini → AST SpaceMobile (ASTS)
ASTS is building satellite broadband that connects directly to ordinary smartphones. If successful, it could address billions of mobile subscribers and areas where traditional cellular infrastructure doesn’t economically work.
Runner-up: Rocket Lab (RKLB)
GPT-5.5 → TransMedics (TMDX)
A very different pick. TMDX already has meaningful revenue, profitability and a strong moat combining organ-preservation technology, clinical infrastructure and logistics. The thesis is that it could become the infrastructure platform for organ transplantation.
Runner-up: Hims & Hers (HIMS)
GPT-5.6 → monday.com (MNDY)
The least “moonshot” answer. MNDY already produces strong cash flow, is growing around 20%, has a relatively small valuation and could expand from project management into CRM, service and AI-powered enterprise workflows. The interesting part is that the 10x math only requires roughly mid-teens long-term growth plus margin expansion… I don’t get this one either.
Runner-up: Klaviyo (KVYO)
The closest thing to consensus: Rocket Lab appeared in 4 of the 7 models’ top picks or runner-ups, while Oklo was selected #1 by two models.
What I found more interesting than the individual stocks is how different the approaches were. Some models preferred highly asymmetric bets like nuclear and space, while others favored companies that already have revenue, profitability and a clearer path to compounding.
Apparently the AI-approved path to a 10-bagger portfolio is some combination of rockets, nuclear reactors, organ transplants and project-management software. Seems diversified enough. 😂
Which one would you pick if you had to hold it until 2036?